These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17285465)

  • 1. Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease.
    Geerts H
    IDrugs; 2007 Feb; 10(2):121-33. PubMed ID: 17285465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease.
    Gasparini L; Ongini E; Wilcock D; Morgan D
    Brain Res Brain Res Rev; 2005 Apr; 48(2):400-8. PubMed ID: 15850679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
    Imbimbo BP; Peretto I
    Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitroflurbiprofen (NicOx).
    Scatena R
    Curr Opin Investig Drugs; 2004 May; 5(5):551-6. PubMed ID: 15202730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals.
    Galasko DR; Graff-Radford N; May S; Hendrix S; Cottrell BA; Sagi SA; Mather G; Laughlin M; Zavitz KH; Swabb E; Golde TE; Murphy MP; Koo EH
    Alzheimer Dis Assoc Disord; 2007; 21(4):292-9. PubMed ID: 18090435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecule of the month. MPC-7869 (Flurizan).
    Drug News Perspect; 2005 Mar; 18(2):141. PubMed ID: 15883622
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
    Peretto I; Radaelli S; Parini C; Zandi M; Raveglia LF; Dondio G; Fontanella L; Misiano P; Bigogno C; Rizzi A; Riccardi B; Biscaioli M; Marchetti S; Puccini P; Catinella S; Rondelli I; Cenacchi V; Bolzoni PT; Caruso P; Villetti G; Facchinetti F; Del Giudice E; Moretto N; Imbimbo BP
    J Med Chem; 2005 Sep; 48(18):5705-20. PubMed ID: 16134939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell neurotoxicity.
    Klegeris A; Maguire J; McGeer PL
    J Neuroimmunol; 2004 Jul; 152(1-2):73-7. PubMed ID: 15223239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
    Stock N; Munoz B; Wrigley JD; Shearman MS; Beher D; Peachey J; Williamson TL; Bain G; Chen W; Jiang X; St-Jacques R; Prasit P
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2219-23. PubMed ID: 16455248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-flurbiprofen: isomeric ballast or active entity of the racemic compound?
    Geisslinger G; Menzel-Soglowek S; Beck WS; Brune K
    Agents Actions Suppl; 1993; 44():31-6. PubMed ID: 8372732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of flurbiprofen, ketoprofen and etodolac enantiomers by pre-column derivatization RP-HPLC and application to drug-protein binding in human plasma.
    Jin YX; Tang YH; Zeng S
    J Pharm Biomed Anal; 2008 Apr; 46(5):953-8. PubMed ID: 18329215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the diagnosis and treatment of Alzheimer's disease.
    Salloway S
    Med Health R I; 2006 May; 89(5):166-8. PubMed ID: 16764297
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioinversion of R-flurbiprofen to S-flurbiprofen at various dose levels in rat, mouse, and monkey.
    Leipold DD; Kantoci D; Murray ED; Quiggle DD; Wechter WJ
    Chirality; 2004 Jul; 16(6):379-87. PubMed ID: 15190583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NC-531 (Neurochem).
    Geerts H
    Curr Opin Investig Drugs; 2004 Jan; 5(1):95-100. PubMed ID: 14983981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in Alzheimer's disease drug discovery: an update.
    Williams M
    Curr Opin Investig Drugs; 2009 Jan; 10(1):23-34. PubMed ID: 19127484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.
    Quann EJ; Khwaja F; Zavitz KH; Djakiew D
    Cancer Res; 2007 Apr; 67(7):3254-62. PubMed ID: 17409433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status.
    Knadler MP; Brater DC; Hall SD
    J Pharmacol Exp Ther; 1989 May; 249(2):378-85. PubMed ID: 2724130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.